Drug Design For Flavivirus Proteases: What Are We Missing?

Author(s): Anders Poulsen, Congbao Kang, Thomas H. Keller

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 21 , 2014

Become EABM
Become Reviewer


Even though a number of groups have identified peptidic inhibitors for DENV and WNV proteases, and several high throughput screening campaigns have been performed, the progress towards drug candidates has been very slow. This is in stark contrast to the related NS3/NS4A protease of HCV for which two peptidomimetic drugs were approved in 2011. In this review we will compare the NS3 proteases of the flaviviruses WNV and DENV with that of HCV, and answer the question whether the flavivirus proteases are inherently more challenging, or whether the lack of success is simply due to the limited resources that have so far been invested in these neglected disease targets.

Keywords: Flaviviral protease, dengue virus, west nile virus, hepatitis C virus, NS3 protease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [3422 - 3427]
Pages: 6
DOI: 10.2174/13816128113199990633
Price: $65

Article Metrics

PDF: 50